UTI Healthcare Fund Direct Growth

Equity

Sector - Healthcare

NAV as on 01-04-2025

₹ 297.31

Inception Returns

16.3%

/yr

Historical NAV & Returns

Absolute

▲

▼

442 people have invested ₹ 70.7L in UTI Healthcare Fund Direct Growth in the last three months

About UTI Healthcare Fund Direct Growth

UTI Healthcare Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

UTI Healthcare Fund Direct Growth has ₹1057 Cr worth of assets under management (AUM) as on Feb 2025 and is less than category average.
The fund has an expense ratio 1.2.

Returns

UTI Healthcare Fund Direct Growth has given a CAGR return of 16.26% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 21.26%, 20.77% and 28.65% respectively.

Holdings

UTI Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Ajanta Pharma Ltd, Glenmark Pharmaceuticals Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of UTI Healthcare Fund Direct Growth

The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. UTI Healthcare Fund Direct Growth has no lock in period.

UTI Healthcare Fund Direct Growth Overview

Expense ratio	1.23%
Benchmark	S&P BSE Healthcare PR
AUM	₹1057 Cr
Inception Date	1 January, 2013
Min Lumpsum/SIP	₹5000/₹500
Exit Load	1.0%
Lock In	No Lock-in
TurnOver	24.75%
STCG	Selling mutual fund before 1 year, returns taxed at 20%.
LTCG	After 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk	Very High Risk

INDmoney Rank for UTI Healthcare Fund Direct Growth

IND ranking is not available for this fund.

Beats FD returns for both 3Y & 5Y duration

No bad points found for this fund.

Trailing Returns

as on (01-Apr-25)

Period	UTI Healthcare Fund Direct Growth	Nifty 500	sector - healthcare
1M	8.2%	6%	7.5%
3M	-8.3%	-6.3%	-8.9%
6M	-7%	-13.2%	-7.4%
1Y	21.3%	2.8%	16.4%
3Y	20.8%	11.8%	18.4%
5Y	28.7%	25.5%	27%

Fund Distribution

as on (28-Feb-25)

Equity 99.6%
Debt & Cash 0.5%

Small cap

43.5%

Large cap

28.9%

Mid cap

26.3%

Sector Allocation

Feb'25

Jan'25

Dec'24

Health

98.7%

Basic Materials

1.3%

All changes are between Dec'24 and Feb'25

	Dec'24
Fund Returns	2.03%
Nifty 500	-2.02%

Parameters	Feb'25	Jan'25	Dec'24
AUM	₹ 1.1K Cr	₹ 1.2K Cr	₹ 1.2K Cr

AUM of the fund stands at 1.1K Cr as of Feb'25
AUM decreased by 93.3 Cr between Feb'25 and Jan'25

Top Stocks bought last month

Suven Pharmaceuticals Ltd's allocation increased from 2.69% to 3.39%

Gland Pharma Ltd's allocation increased from 3.19% to 3.53%

Eris Lifesciences Ltd Registered Shs's allocation increased from 2.67% to 2.94%

Top Stocks sold last month

Sun Pharmaceuticals Industries Ltd's allocation decreased from 10.99 % to 10.93 %

Dr Reddy's Laboratories Ltd's allocation decreased from 4.89 % to 4.57 %

Glenmark Pharmaceuticals Ltd's allocation decreased from 3.91 % to 3.74 %

Large Cap allocation has gone down from 32.4% to 28.9%

Small Cap allocation has gone up from 34.2% to 43.5%

Mid Cap allocation has gone up from 25.9% to 26.3%

Cash allocation has gone down from 2.3% to 0.4%

Top 2 Sectors in February were Health, Basic Materials

Feb'25

Health

99%

Basic Materials

Jan'25

Health

99%

Basic Materials

Equity

Holdings	Weight%	1M Change
Sun Pharmaceuticals Industries Ltd	10.93%	0%
Cipla Ltd	6.19%	0%
Dr Reddy's Laboratories Ltd	4.57%	-8%
Ajanta Pharma Ltd	4.43%	0.9%
Glenmark Pharmaceuticals Ltd	3.74%	0%

See all

Returns %
Fund Ratios
Overview

Funds	1Y Returns	3Y Returns	5Y Returns	Since Inception
UTI Healthcare Fund Direct Growth	21.26%	20.77%	28.65%	16.26%
SBI Healthcare Opportunities Fund Direct Growth	21.09%	24.2%	30.72%	18.26%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth	20.88%	23.86%	32.79%	22.44%
LIC MF Healthcare Fund Direct Growth	20.73%	17.69%	24.52%	20.27%

See all

Gainers
Losers

Top Growth Drivers	1M Return
Sai Life Sciences Ltd	7.9%
Suven Pharmaceuticals Ltd	1%

Fund	Feb'25	Jan'25	Dec'24
No of Holdings	45	45	45
Top 5 Company Concentration	29.9%	30.2%	30.7%
Company having highest exposure	Sun Pharmaceuticals Industries Ltd (10.9%)	Sun Pharmaceuticals Industries Ltd (11%)	Sun Pharmaceuticals Industries Ltd (11.1%)
No of Sectors	2	2	3
Top 5 Sectors Concentration	100%	100%	100%
Sector having highest exposure	Health (98.7%)	Health (98.6%)	Health (98.4%)

We are taking more time than usual

Fund House

UTI Asset Management Co Ltd

Total Schemes

See all UTI schemes

Total AUM

₹2.35L Cr

as on 28-Feb-2025

Address

PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051

Phone

+912266786666

Website

pms_care@uti.co.in

Mutual Fund Insights

In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 31.15% return, outperforming this fund by 9.89%.

This fund expense ratio is slightly on the lower side within the category (sector - healthcare). Its expense ratio is 1.23% which is lower than the category average expense ratio of 1.41%.

Over the last 1 year, this fund has decreased expense ratio by 9.6% moving from 1.36 to 1.23.

Over the last 3 months, this fund has experienced a 12.1% drop in AUM moving from 1.20K Cr to 1.05K Cr.

In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 32.79% return, outperforming this fund by 4.14% per annum.

In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 24.2% return, outperforming this fund by 3.43% per annum.

UTI Healthcare Fund Direct Growth Highlights

Very High Risk

Investors understand that their principal will be at Very High Risk

About the fund

This fund has delivered an average annual returns of 16.26% since inception which is less than its category average return of 17.05%

Fund Allocations

This fund has an allocation of 99.55% in Equity, 0% in Debt and 0.45% in Cash related instruments

AUM size ₹1057 Cr

This fund has AUM of ₹1057 Cr which is less than its category average of ₹ 1725 Cr

Expense Ratio 1.23%

This fund has an expense ratio of 1.23% which is less than its category average expense ratio of 1.45%

Frequently Asked Questions for UTI Healthcare Fund Direct Growth

The current NAV of UTI Healthcare Fund Direct Growth is ₹297.31 as on 01-Apr-2025.

Existing (Absolute + CAGR) as on 01-Apr-2025.

UTI Healthcare Fund Direct Growth	Absolute Returns	CAGR Returns
1 Month Returns	8.18%	8.18%
6 Month Returns	-6.97%	-6.97%
1 Year Returns	21.26%	21.26%
3 Years Returns	76.14%	20.77%
5 Years Returns	252.46%	28.65%

With INDmoney, the process of investing is very simple and involves zero commission.

Click Buy on the fund name.
Input the amount you are looking to invest.
Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
Select your bank account and proceed with Payment.

1.23% as on March 2025

₹1057 Cr as on March 2025

Sun Pharmaceuticals Industries Ltd(10.93%), Cipla Ltd(6.19%), Dr Reddy's Laboratories Ltd(4.57%), Ajanta Pharma Ltd(4.43%), Glenmark Pharmaceuticals Ltd(3.74%) as on March 2025

The alpha ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:

Fund Name	Alpha 1 Year	Alpha 3 Years	Alpha 5 Years
UTI Healthcare Fund Direct Growth	2.35	1.26	1.54

As on March 2025

The alpha for UTI Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.

The Beta ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:

Fund Name	Beta 1 Year	Beta 3 Years	Beta 5 Years
UTI Healthcare Fund Direct Growth	1.02	0.96	0.94

As on March 2025

The Beta for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.

The sharpe ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:

Fund Name	Sharpe Ratio 1 Year	Sharpe Ratio 3 Years	Sharpe Ratio 5 Years
UTI Healthcare Fund Direct Growth	0.71	0.84	1.13

As on March 2025

The sharpe ratio for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.

The standard deviation for the UTI Healthcare Fund Direct Growth for various period is as follows:

Fund Name	Standard Deviation 1 Year	Standard Deviation 3 Years	Standard Deviation 5 Years
UTI Healthcare Fund Direct Growth	20.55	16.7	19.39

As on March 2025

Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.

Sortino ratio is 1.49 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.

Information ratio is 0.31 as on March 2025. It tells the consistency of the fund in generating superior risk-adjusted performance

The Exit load of UTI Healthcare Fund Direct Growth is 1%

UTI Healthcare Fund Direct Growth

Historical NAV & Returns

About UTI Healthcare Fund Direct Growth

Key Parameters

Returns

Holdings

Taxation

Investment objective of UTI Healthcare Fund Direct Growth

Minimum Investment and lockin period

UTI Healthcare Fund Direct Growth Overview

INDmoney Rank for UTI Healthcare Fund Direct Growth

Trailing Returns

Fund Distribution

Monthly Changes

Top Holdings

Peer Comparison

Gainers & Losers

Concentration Analysis

AMC Details

Mutual Fund Insights

UTI Healthcare Fund Direct Growth Highlights

Very High Risk

About the fund

Fund Allocations

AUM size ₹1057 Cr

Expense Ratio 1.23%

Frequently Asked Questions for UTI Healthcare Fund Direct Growth

What is the current NAV of UTI Healthcare Fund Direct Growth?

What are the average returns of UTI Healthcare Fund Direct Growth?

How do I invest in UTI Healthcare Fund Direct Growth?

What is the expense ratio of UTI Healthcare Fund Direct Growth?

What is net assets under management (AUM) of UTI Healthcare Fund Direct Growth?

What are the top 5 holdings of UTI Healthcare Fund Direct Growth?

What is the alpha of UTI Healthcare Fund Direct Growth?

What is the beta of UTI Healthcare Fund Direct Growth??

What is the sharpe ratio of UTI Healthcare Fund Direct Growth?

What is the standard deviation of UTI Healthcare Fund Direct Growth?

What is the Sortino ratio of UTI Healthcare Fund Direct Growth?

What is the information ratio of UTI Healthcare Fund Direct Growth?

What is the exit load of UTI Healthcare Fund Direct Growth?